| Title | Final report from intergroup NCCTG 86-72-51 (Alliance): a phase 3 randomized clinical trial of high dose versus low dose radiation for adult low-grade glioma. |
| Publication Type | Journal Article |
| Year of Publication | 2020 |
| Authors | Breen WG, S Anderson K, Carrero XW, Brown PD, Ballman KV, O'Neill BP, Curran WJ, Abrams RA, Laack NN, Levitt R, Galanis E, Buckner JC, Shaw EG |
| Journal | Neuro Oncol |
| Date Published | 2020 Jan 30 |
| ISSN | 1523-5866 |
| Abstract | BACKGROUND: The optimal radiation dose for adult supratentorial low grade glioma is unknown. The aim of this study was to provide a final update on oncologic and cognitive outcomes of high dose versus low dose radiation for low-grade glioma. METHODS: Between 1986 and 1994, 203 patients with supratentorial low grade glioma were randomized (1:1) to 50.4 Gy in 28 fractions versus 64.8 Gy in 36 fractions after any degree of resection. RESULTS: For all patients, median OS was 8.4 years (95% CI: 7.2 - 10.8). Median progression-free survival (PFS) was 5.2 years (95% CI: 4.3 - 6.6). Median follow-up is 17.2 years for the 33 patients still alive. CONCLUSIONS: Long-term follow-up indicates no benefit to high-dose over low-dose radiation for low-grade gliomas. Cognitive function appeared to be stable after radiation as measured by MMSE. |
| DOI | 10.1093/neuonc/noaa021 |
| Alternate Journal | Neuro-oncology |
| PubMed ID | 32002556 |
Final report from intergroup NCCTG 86-72-51 (Alliance): a phase 3 randomized clinical trial of high dose versus low dose radiation for adult low-grade glioma.
Submitted by chz4003 on February 4, 2020 - 1:49pm
Division:
Biostatistics
Category:
Faculty Publication